Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07902752). This is a study registration, not published results. Lead sponsor: George Washington University. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 100 participants (ESTIMATED). Conditions: Obesity & Overweight, Respiratory Depression, Intranasal Drug Administration, Oxytocin, Bariatric Surgery. Interventions: DRUG: Intranasal Oxytocin 40 i.u.; DRUG: Intranasal Placebo Spray. Primary outcome measures: Postoperative Hypopnea Events , 2.5 hours after index surgery; Postoperative Apnea Events , 2.5 hours after index surgery; Oxygen Levels , 2.5 hours after index surgery. Brief summary: Drug overdose is a national crisis. The primary cause of death associated with opioids is opioid-induced respiratory depression. Naloxone (Narcan) which is the first line of defense for opioid overdose can reverse OIRD (Opioid-Induced Respiratory Depression), but in post-operative patients it will abolish pain control. There are no medications that can prevent OIRD. Pre-clinical studies provided evidence that intranasal (administered via a nasal spray) oxytocin may prevent and treat OIRD without interfering with pain control.